📈 Price History

Ratio Health

— Excellent

— Good

— Average

— Poor

By Category

📊 Sector Averages

About

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.

Key Ratios Snapshot

📈 Growth Pattern

⚡ Latest Quarter —

See full financials →

📊 Quick Scorecard

Loading…

⭐ Superinvestors Holding NTLA

View All Superinvestors →

Manager	Shares	Value	% of Fund	Period
Cathie Wood ARK Investment Management	14.51M	$186.0M	1.45%	Mar 2026
Steve Cohen Point72 Asset Management	270.0K	$3.5M	0.00%	Mar 2026

SEC Form 13F data. 45-day lag from quarter end.

🔍 Concall Decoded

🎙 Management Tone Tracker Confident Specific → Stable 4 quarters analysed

Q4 2024

Confident Specific

Management repeatedly gave concrete forward-looking targets (550 patients enrolled in MAGNITUDE by year-end, BLA filing for HAE in 2026, cash runway into H1 2027) and used specific verbs like 'expect', 'on track', 'confident' with quantified milestones.

Q1 2025

Confident Specific

Management uses phrases like 'tremendous progress', 'well ahead of schedule', 'confident in our plans', and 'very excited' repeatedly. Specific milestones (first patient dosed in two Phase 3 studies) are cited with concrete timelines (e.g., enrollment complete by Q3 2025).

Q2 2025

Confident Specific

Management uses phrases like 'excellent execution', 'meeting or exceeding all objectives', and provides specific enrollment numbers (e.g., 650 patients by year-end, 1,200 target for MAGNITUDE) and precise timelines (HAELO enrollment completed in Q3). They repeatedly emphasize 'strong interest' and 'unprecedented' enrollment pace.

Q4 2025 latest

Confident Specific

Management repeatedly used confident language like 'we believe the lonvo-z arm will be highly competitive', 'exciting building toward the world's first phase 3 readout', and provided specific numbers on market research (99% patient likely, 92% HCP) and financial milestones (cash runway into 2H 2027). However, clinical hold discussion was cautiously optimistic, acknowledging progress but avoiding definitive timelines.

Guidance Reliability Pending · <3Q data

Investor Lens

The investment thesis for Intellia is modestly stronger for the HAE program (lonvo-z) due to compelling phase 2 pooled data, high patient/physician interest, and clear path to BLA. The ATTR program (nex-z) remains uncertain with the clinical hold on the larger CM study unresolved, though the smaller PN study is restarting. The key change is the lifted hold on MAGNITUDE-2, which reduces some risk, but the CM hold and lack of clarity on timing keep a cloud over that program. Investors should watch the mid-2025 phase 3 HAELO readout (lonvo-z) and any resolution of the MAGNITUDE clinical hold. The cash runway into 2H 2027 provides cushion but depends on enrollment restart and cost control. The company's claim that a mid-single-digit HAE market share could fund operations is a significant positive if achieved, but it hinges on successful launch.

AI-generated concall tone analysis · Updated 2026-06-09 · Not investment advice

🎙 Management Tone Confident Specific → Stable 4 quarters Full tone analysis in Intelligence →

📊 MIXED Intellia $605M cash; HAE phase 3 data mid-2025; ATTR hold progress

Revenue & Profitability

Fourth quarter 2025 collaboration revenue was $23 million, up from $12.9 million in the prior year quarter, driven by the SparingVision termination and Regeneron reimbursement. R&D expenses were $88.7 million, down from $116.9 million. Net loss was $95.8 million, compared to $128.9 million in the prior year quarter. Cash, cash equivalents, and marketable securities were $605.1 million as of December 31, 2025, down from $861.7 million a year earlier.

Outlook

Management highlighted substantial unmet need in HAE despite available therapies, noting that only 20% of patients are attack-free for 12 months on current treatments. They believe lonvo-z's profile as a one-time therapy with high attack-free rates (76% of patients beyond one year in pooled analysis) addresses this need. For ATTR amyloidosis, they see strong potential based on positive phase 1 data and are working with FDA to address the clinical hold on the cardiomyopathy study.

Growth Drivers

The primary growth driver is lonvo-z for HAE, with phase 3 top-line data expected mid-2025 and a BLA submission in the second half of 2025. The company is building commercial infrastructure and targeting the approximately 7,000 treated HAE patients in the US. Another driver is nex-z for ATTR amyloidosis, with MAGNITUDE-2 (polyneuropathy) enrollment resuming and expected to complete by end of 2025. Management estimates that achieving a mid-single digit market share in HAE could fund the entire company's operations.

Balance Sheet & CapEx

Not discussed in this earnings call.

Margins

Not discussed in this earnings call.

Key Risks

Key risks include the ongoing clinical hold on the MAGNITUDE (cardiomyopathy) study and the need to implement mitigation strategies for liver enzyme elevations. One patient in MAGNITUDE died from a ruptured duodenal ulcer after elevated transaminases. There is also operational risk in restarting MAGNITUDE-2 enrollment and completing it on time. Competition from other HAE and ATTR therapies could affect market adoption.

Generated by AI · Q4 2025 results · Not investment advice

✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter

🔍

🔎 See cross-company document search → ?

📞 Earnings Call Transcripts (5)

Q2 2026 Q2 2026 2026-08-06

Major clinical progress was achieved in phase III programs for HAE and ATTR, with positive efficacy and safety data, a rolling BLA submission for lonvo-z, and resumed nex-z trials. Financially, cash reserves increased to $628.4 million, supporting operations into 2028.

Q4 2025 Q4 2025 2026-02-26

Rapid progress in phase 3 trials for gene-editing therapies in ATTR amyloidosis and HAE, with strong patient and physician interest in lonvo-z. Financials show improved net loss and robust cash runway into 2027, while FDA engagement continues for MAGNITUDE trial.

Q2 2025 Q2 2025 2025-08-07

Exceeded clinical and operational goals in H1 2025, with accelerated phase III enrollment and strong interim data for lead programs. Cash runway extends into 2027, supporting expanded trials and commercial readiness.

Q1 2025 Q1 2025 2025-05-08

Achieved key clinical milestones with rapid phase III enrollment in HAE and ATTR programs, maintained a strong cash position with a runway into 2027, and executed cost-saving restructuring. Regulatory progress and commercial readiness position the company for upcoming product launches.

Q4 2024 Q4 2024 2025-02-27

Strong progress in late-stage HAE and TTR amyloidosis programs, with robust phase III enrollment and positive clinical data supporting potential functional cures. Restructuring and pipeline focus are expected to reduce operating expenses and extend cash runway into 2027, while commercial readiness efforts accelerate for anticipated launches.

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯

Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.

📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.